Often G9a and GLP activities are described as inhibitory targets for cancer treatment (Casciello et al., 2015; Charles et al., 2019; Milite et al., 2019); for example, Huang and colleagues reported G9a and GLP to be overexpressed in a variety of cancers, denoting them as candidate oncogenes (Huang et al., 2010). This evidence concerns the gene EHMT2 and cancer.